Impel NeuroPharma is a late-stage biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) diseases using its proprietary Precision Olfactory Delivery (POD®) system. Its lead product candidate is INP104, proposed trade name TRUDHESA™, for the acute treatment of migraine; other pipeline candidates include INP105 for agitation and aggression in patients with autism and INP107 for OFF episodes in Parkinson’s disease. The company announced FDA acceptance of the TRUDHESA NDA in January 2021 with a Prescription Drug User Fee Act target action date of September 6, 2021. Impel said it closed a $50 million debt facility that strengthens its balance sheet and positions the company to execute a potential launch and commercialization of TRUDHESA. The initial $20 million tranche funded at closing extends Impel’s expected cash runway through the fourth quarter of 2022. The company continues to develop its POD technology, which it says has demonstrated successful results in multiple clinical trials to date. Impel NeuroPharma develops therapies for central nervous system (CNS) disorders and uses its Precision Olfactory Delivery (POD) nasal drug-delivery device to deliver liquid or dry powder to the upper nasal cavity. The company is advancing multiple clinical-stage programs, including INP104 in Phase 3 for acute migraine, INP103 in Phase 2 for reversal of OFF episodes in Parkinson’s disease, and INP105 in Phase 1 for acute agitation in bipolar I and schizophrenia. Led by CEO Jon Congleton, Impel intends to use newly raised funds to accelerate its existing clinical development portfolio in CNS disorders. The POD device is designed to deliver drugs in a consistent and predictable manner to the upper nasal cavity. The company is focused on addressing CNS indications with unmet medical need. Impel NeuroPharma is a clinical-stage biotechnology company based in Seattle, WA developing intranasal drug-device combination products built on its Precision Olfactory Delivery (POD) nasal delivery platform. The POD platform delivers therapeutics to the upper nasal cavity to leverage the vascular-rich olfactory region for improved bioavailability and has potential to target the brain via the olfactory and trigeminal nerves. The company is developing candidates for migraine, Alzheimer’s and Parkinson’s disease and expects new indications to enter the clinic in 2017. Led by CEO John Hoekman, Impel intends to continue developing combination products internally and through pharmaceutical company partnerships. The company secured financing to advance clinical development of its lead compounds. Impel NeuroPharma is a biopharmaceutical company developing a Precision Olfactory Delivery (POD) platform to enhance delivery of drugs to the brain and central nervous system. POD deposits drugs deep into the upper nasal cavity to enable CNS delivery and is a handheld, cost-effective, non-invasive device that can be self-administered by patients, caregivers, or clinicians. Impel is advancing a pipeline of internal programs including INP-104 for drug-resistant migraine, INP-101 for pain management, and INP-102 for Alzheimer’s disease. The company says INP-104 is in late-stage development for patients who have failed front-line triptan therapy, INP-101 is in clinical development for patients needing rapid analgesia who cannot tolerate systemic opioids, and INP-102 is in multiple later-stage trials including Phase 2 and Phase 3a. Impel plans to commercialize the POD technology and continue its clinical development programs to bring CNS therapeutics to market. The company announced the first close of a Series B financing—part of a $12 million round—led by 3M New Ventures; other financial details were not disclosed, and Impel is based in Seattle, Washington.

Total raised

$166M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Jul 2021